An anti-FGF23 monoclonal antibody, burosumab, has recently been shown to be safe and effective in controlling signs and symptoms in pediatric and adult patients with hypophosphatemic rickets due to FGF-23 excess. The gene discussed is FGF23; the disease is Dent disease.